0.95
9.20%
+0.08
Quoin Pharmaceuticals Ltd ADR stock is currently priced at $0.95, with a 24-hour trading volume of 160.86K.
It has seen a +9.20% increased in the last 24 hours and a -63.60% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.85 pivot point. If it approaches the $0.98 resistance level, significant changes may occur.
Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Financials Data
Quoin Pharmaceuticals Ltd ADR (QNRX) Net Income 2023
QNRX net income (TTM) was -$9.74 million for the quarter ending June 30, 2023, a +44.57% increase year-over-year.
Quoin Pharmaceuticals Ltd ADR (QNRX) Cash Flow 2023
QNRX recorded a free cash flow (TTM) of -$7.56 million for the quarter ending June 30, 2023, a +15.48% increase year-over-year.
Quoin Pharmaceuticals Ltd ADR (QNRX) Earnings per Share 2023
QNRX earnings per share (TTM) was -$45.93 for the quarter ending June 30, 2023, a +93.74% growth year-over-year.
Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Latest News
Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know
Benzinga
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
GlobeNewswire Inc.
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
GlobeNewswire Inc.
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
Benzinga
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
Benzinga
About Quoin Pharmaceuticals Ltd ADR
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia.
Cap:
|
Volume (24h):